GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40698)

  • GC92010 structure
    GC92010SJB2-043 analog (trifluoroacetate salt)
    Purity: >95.00%

    SJB2-043 analog (trifluoroacetate salt) es un inhibidor de OTUB1 y USP8 (IC50s = 0.17 y 0.28 nM, respectivamente) y un derivado del complejo USP1/UAF1 y el inhibisjb2-043 del sscov-2 PLPro.

  • GC92012 structure
    GC92012MT-1207 (hydrochloride)
    Purity: >98.00%

    MT-1207 (hydrochloride) es un antagonista activo y selectivo del receptor adrenérgico ≥ 1 y 5-HT2A. El MT-1207 muestra IC50< 0,1 nM, 0,15 nM, 1,40 nM y 0,27 nM para − 1A, − 1B, − 1D y 5-HT2A, respectivamente.

  • GC92014 structure
    GC92014PKN3 Inhibitor Compound 16
    CAS: 2361545-75-5
    Purity: >98.00%

    PKN3 Inhibitor Compound 16 es un inhibidor de la proteína quinasa de serina/treonina N3 (IC50 = 14 nM).

  • GC92015 structure
    GC92015WYneN
    CAS: 3052492-38-0
    Purity: >95.00%

    WYneN es una sonda quimioselectiva para la detección de proteínas sulfeniladas en células vivas.

  • GC92016 structure
    GC92016WYneO
    CAS: 1648555-11-6
    Purity: >95.00%

    WYneO es una sonda para la detección de proteínas sulfeniladas.

  • GC92018 structure
    GC92018N,N′-Diferuloylputrescine
    CAS: 42369-86-8
    Purity: >95.00%

    N,N′-Diferuloylputrescine es una poliamina que se ha encontrado en Z. mays y tiene diversas actividades biológicas.

  • GC92019 structure
    GC920191-Octadecyl-2-hydroxy-sn-glycero-3-phosphate (sodium salt)
    Purity: >95.00%

    1-Octadecyl-2-hydroxy-sn-glycero-3-phosphate (sodium salt) (1-octadecilpa) es un análogo de LPA que contiene alcohol estearílico en la posición sn-1.

  • GC92022 structure
    GC920224-hydroxy Nonenal Glutathione-d3
    Purity: >99.00%

    4-hydroxy Nonenal Glutathione-d3 (4-HNE-GSH-d3) está destinado para su uso como un estándar interno para la cuantide 4-HNE-GSH por GC- o LC-MS.

  • GC92023 structure
    GC92023PTX80
    CAS: 2376297-69-5
    Purity: >95.00%

    PTX80 es un antagonista de P62 (IC50 = 31,18 nM para el receptor humano).

  • GC92024 structure
    GC92024BPN-01
    Purity: >90.00%

    BPN-01 es una sonda fluorescpara detectar células cancerosas.

  • GC92026 structure
    GC92026D-Val-Leu-Lys-pNA
    CAS: 63589-93-5
    Purity: >98.00%

    D-Val-Leu-Lys-pNA es un sustrcolorpara la plasmina.

  • GC92028 structure
    GC92028UCM-05194 (ammonium salt)
    Purity: >95.00%

    UCM-05194 (ammonium salt) es un agonista del receptor de ácido lisofosfatídico 1 LPA1.

  • GC92029 structure
    GC92029N-Lithocholyl-L-Leucine
    CAS: 2095154-73-5
    Purity: >95.00%

    N-Lithocholyl-L-Leucine es un ácido biliar conjucompuesto de ácido litocólico y l-leucina.

  • GC92030 structure
    GC92030Debio 0123 (hydrochloride)
    Purity: >98.00%

    Debio 0123 (hydrochloride) es un inhibidor de la quinasa de punto de control WEE1 IC50 = 0,8 nM.

  • GC92031 structure
    GC92031GPX4 Inhibitor 17
    Purity: >98.00%

    GPX4 Inhibitor 17 es un inhibidor de la glutatión peroxid4 (GPX4) y un inductor de la ferroptosis.

  • GC92033 structure
    GC92033HPG1860
    CAS: 2226133-29-3
    Purity: >98.00%

    HPG1860 es un agonista del receptor farnesox (FXR).

  • GC92036 structure
    GC92036MCL0020 (trifluoroacetate salt)
    Purity: >98.00%

    MCL0020 (trifluoroacetate salt) es un antagonista del receptor 4 MC4R de melanocortina.

  • GC92037 structure
    GC92037JQKD82 (hydrochloride)
    CAS: 2863676-87-1
    Purity: >98.00%

    JQKD82 (hydrochloride) es una forma de profármaco de KDM5-C49, un inhibide Jumonji AT-rich Interactive domain 1A (JARID1A), también conocido como lisina específica demetilasa 5A (KDM5A).

  • GC92039 structure
    GC92039NO-Rosa5

    NO-Rosa5 es un donante de óxido nítrico fotocontrolable (NO) para uso in cellulo y ex vivo.

  • GC92040 structure
    GC92040SGC0946 (trifluoroacetate salt)
    Purity: >98.00%

    SGC0946 (trifluoroacetate salt) es un inhibide la metiltransferasa DOT1L (IC50 = 0.3 nM).

  • GC92043 structure
    GC920439(10)-Nitrooleate
    CAS: 1092676-99-7
    Purity: >95.00%

    9(10)-Nitrooleate es una mezcla de las moléculas de señalización lipíendde nitroalqueno 9-nitrooleato.

  • GC92044 structure
    GC92044H1L1A1B3
    CAS: 3097638-09-7
    Purity: >95.00%

    H1L1A1B3 es un lípido catiónico ionizable que se ha utilizado en combinación con otros lípidos en la formación de LNPs para la entrega de ARN circular (circRNA) in vitro e in vivo.

  • GC92048 structure
    GC92048O12-D3-I3
    Purity: >95.00%

    O12-D3-I3 es un lípido catiónico ionizable (pKa = 6.39) que se ha utilizado en la generación de nanopartículas lipídicas (LNPs) para la administración de siRNA in vitro e in vivo.

  • GC92051 structure
    GC92051Alkyne-Cyclo(RGDyK) (trifluoroacetate salt)
    Purity: >98.00%

    Alkyne-Cyclo(RGDyK) (trifluoroacetate salt) es una forma clicclicde la integrina − V − 3 ligde péptido cícliccyclo (RGDyK).